Potential Role of CC Chemokines and their Receptors in the Development of Respiratory Diseases

Lin Tong, YaoLi Wang, Jing Bi, Dong Yang, ChunXue Bai* and XiangDong Wang*

Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China

Abstract: Increasing evidence suggests that the chemokine system coordinates leukocyte migration in immunity and inflammation, involving in the pathogenesis of many pulmonary diseases. Chemokines are small proteins which interact with specific receptors to exert their chemotactic functions for inflammatory cells and constitutive cells. Among the complex system, CC chemokine receptors (CCRs) represent a subfamily of chemokine receptor, which is considered to play an important role in the pathogenesis of diseases characterized by disordered inflammation and immunity, among which some respiratory diseases, such as asthma, chronic obstructive pulmonary disease, acute lung injury, comprise one important part. The present paper reviewed the research of possible relationship and progress between this system and human lung diseases. Chemokines and their receptors are essential components of Th1- and Th2-mediated responses via the recruitment of lymphocytes and macrophages. The local expression of homeostatic chemokines in pulmonary also plays an important role in protective immune responses. Thus, it is important to understand the potential role of CCRs in respiratory diseases and it may provide exciting new targets for therapeutic intervention.

Keywords: Chemokines, CCR, lung, asthma, COPD.

INTRODUCTION

Chemokine receptors are members of G-protein-coupled receptor superfamilies, which are characterized by seven-transmembrane-spanning protein coupled to heterotrimeric G protein. As their ligands, chemokines are a large family of chemoattractant cytokines, playing an important role during episodes of tissue inflammation and injury, by binding to specific chemokine receptors to activate and recruit a wide variety of cell types, notably leukocytes. Both chemokines and their receptors have been implicated in a host of clinically important diseases, including a series of respiratory diseases. The current review focuses more on understanding the role of CCRs in the pathogenesis of respiratory diseases (Table 1) and possible interventional therapeutic strategies being used for patients.

Chemokines are small proteins with four conserved cysteines forming two essential disulphide bonds (Cys1–Cys3 and Cys2–Cys4). The approximately 50 chemokines and 20 receptors identified to date are classified into four families, on the basis of the pattern of the first two of four cysteine residues of the ligand. The large CC chemokine family consists of chemokines with the first two cysteine residues adjacent to each other [1, 2]. The CCR family comprises 10 receptors (CCRI-10) with their 25 ligands (CCL), dominating about half of the chemokine and chemokine receptor family. Binding to chemokine receptors results in the dissociation of \( \alpha \) and \( \beta \) subunits of the heterotrimeric G proteins (Fig. 1). This leads to calcium flux and activation of the phosphatidylinositol 3-kinase and the small Rho GTPases signaling pathways and regulates gradient sensing and F-actin polymerization at the leading edge of migrating cell, responsible for cell contraction, adhesion and activation [1]. Their main function is considered to mediate and direct the trafficking and migration of monocytes and lymphocytes. Chemokine receptors are not only expressed by circulating cells but also by tissue resident cells, including epithelia, endothelia, stromal cells, neurons and smooth muscle, and their expression is upregulated in various inflammatory conditions [3].

The lung is a unique organ supplied with blood from both pulmonary and systemic circulations, that deliver blood to the parenchyma and the airways, respectively. Due to the low pressure of the pulmonary system, leukocyte rolling and firm adherence are not required for extravasation. It is suggested that a weak chemoattractic signal per se can induce and mediate migration into the underlying tissue [4]. A number of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), share common pathophysiological processes, like inflammation, independent upon either acute or chronic. Unregulated inflammatory process may lead to histological alterations like fibrosis and remodeling and impairment of lung function. The relationship between chemokine system and respiratory diseases as the new scope for further research and therapeutic targets remains unclear.

ROLE IN ASTHMA

Asthma is a complex immunological and inflammatory disease characterized by the presence of airway inflammation, tissue remodeling and bronchial hyperresponsiveness. It remains to understand the development and interaction of those three key features in the pathogenesis of the lung disease. The inflammatory response characteristically comprises activated T helper type 2 (Th2) lymphocytes, eosino-
Table 1. Role of CC Chemokines and Related CCRs in the Pathogenesis of Respiratory Diseases

<table>
<thead>
<tr>
<th>Respiratory Disease</th>
<th>Key Inflammatory Cell</th>
<th>CC Chemokine</th>
<th>CCR</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
<td>Th2 cell</td>
<td>CCL11 (Eotaxin)</td>
<td>CCR3</td>
<td>Eosinophil recruitment</td>
</tr>
<tr>
<td></td>
<td>Eosinophil</td>
<td>CCL24 (Eotaxin-2)</td>
<td></td>
<td>Eosinophil apoptosis inhibition</td>
</tr>
<tr>
<td></td>
<td>Mast cell</td>
<td>CCL26 (Eotaxin-3)</td>
<td></td>
<td>Enhance macrophage antigen-presenting activity</td>
</tr>
<tr>
<td></td>
<td>CD11b+ CD1c(int) macrophage</td>
<td>CCL17 (TARC)</td>
<td>CCR4</td>
<td>Eosinophil recruitment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CCL22 (MDC)</td>
<td></td>
<td>Th2 cell and iNKT cell recruitment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CCL1 (I-309)</td>
<td>CCR8</td>
<td>Th2 cell recruitment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CCL3 (MIP-1α)</td>
<td>CCR1</td>
<td>ASMC activation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CCL3 (MIP-1α)</td>
<td>CCR8</td>
<td>Neutrophil recruitment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CCL5 (RANTES)</td>
<td></td>
<td>Suppress induction of iNOS</td>
</tr>
<tr>
<td></td>
<td>Neutrophil</td>
<td>CCL2 (MCP-1)</td>
<td>CCR2</td>
<td>Eosinophil recruitment</td>
</tr>
<tr>
<td></td>
<td>Macrophage</td>
<td>CCL3 (MIP-1α)</td>
<td>CCR1</td>
<td>Eosinophil recruitment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CCL5 (RANTES)</td>
<td></td>
<td>Th2 cytokines and chemokines secretion</td>
</tr>
<tr>
<td></td>
<td>Neutrophil</td>
<td>CCL3 (MIP-1α)</td>
<td>CCR1</td>
<td>Neutrophil recruitment</td>
</tr>
<tr>
<td></td>
<td>Macrophage</td>
<td>CCL2 (MCP-1)</td>
<td>CCR2</td>
<td>Neutrophil recruitment</td>
</tr>
<tr>
<td></td>
<td>Lymphocyte</td>
<td>CCL21 (SLC)</td>
<td>CCR7</td>
<td>Neutrophil and eosinophil recruitment</td>
</tr>
<tr>
<td></td>
<td>Neutrophil</td>
<td>CCL11 (Eotaxin)</td>
<td>CCR3</td>
<td>Neutrophil recruitment</td>
</tr>
<tr>
<td></td>
<td>Dendritic cell</td>
<td>CCL20 (MIP-3α)</td>
<td>CCR6</td>
<td>Eosinophil recruitment</td>
</tr>
<tr>
<td></td>
<td>Neutrophil</td>
<td>CCL3 (MIP-1α)</td>
<td>CCR5</td>
<td>CD8+ T cell recruitment/retention</td>
</tr>
<tr>
<td></td>
<td>CD8+T lymphocyte</td>
<td></td>
<td></td>
<td>Macrophage, neutrophil and dendritic cell recruitment</td>
</tr>
<tr>
<td></td>
<td>Macrophage</td>
<td>CCL2 (MCP-1)</td>
<td>CCR2</td>
<td>Profibrotic cytokine secretion</td>
</tr>
<tr>
<td></td>
<td>Lymphocyte</td>
<td>CCL20 (MIP-3α)</td>
<td>CCR6</td>
<td>Neutrophil, lymphocyte and dendritic cell recruitment</td>
</tr>
<tr>
<td>Pulmonary fibrosis</td>
<td>Macrophage</td>
<td>CCL3 (MIP-1α)</td>
<td>CCR1</td>
<td>Neutrophil recruitment</td>
</tr>
<tr>
<td></td>
<td>Lymphocyte</td>
<td>CCL2 (MCP-1)</td>
<td>CCR2</td>
<td>Neutrophil recruitment</td>
</tr>
<tr>
<td></td>
<td>Neutrophil</td>
<td>CCL20 (MIP-3α)</td>
<td>CCR6</td>
<td>Neutrophil, lymphocyte and dendritic cell recruitment</td>
</tr>
<tr>
<td>Airway remodeling</td>
<td>Th2 cell</td>
<td>CCL11 (Eotaxin)</td>
<td>CCR3</td>
<td>Eosinophil recruitment</td>
</tr>
<tr>
<td></td>
<td>Eosinophil</td>
<td>CCL24 (Eotaxin-2)</td>
<td></td>
<td>Profibrotic cytokine secretion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CCL3 (MIP-1α)</td>
<td>CCR1</td>
<td>Th2 cytokines and chemokines secretion</td>
</tr>
</tbody>
</table>

phils and activated mast cells, associated with the etiology [5]. Such specific accumulation of distinct leukocytes is mediated by a number of chemokines, as listed in Table 2. There is a strong evidence from both experimental and clinical studies to confirm the role of chemokines and their receptors, (Fig. 2) including CCR3, CCR4, CCR8, and CCR1, in the development of allergic inflammation [6,7].

**CCR3**

The CC chemokine receptor 3 (CCR3) is expressed on eosinophils, basophils, mast cells, Th2 cells, and interestingly on bronchial epithelial cells and smooth muscle cells. It has been suggested that CCR3 and its ligands may help to co-localize the major cellular components into the lungs during the allergic airway response [8,9]. CCR3/eotaxin (including CCL11, CCL24, CCL26) axis is essential in eosinophils recruitment to the asthmatic lungs. Increased expression of CCL11 and CCL24 at both mRNA and protein levels has been observed at sites of allergic inflammation in both atopic and non-atopic asthmatics and also in the sputum, whilst increased CCL26 expression was noticed in the asthmatic lung at 24 hours following allergen challenge [10]. Although there existed controversies about the role of CCR3 on the induction of lung eosinophilia [11,12], allergen-induced pulmonary eosinophilia has been proposed to be primarily mediated by CCR3 and its ligands eotaxin-1 and eotaxin-2. Eotaxin-2 has a dominant role in OVA-induced airway eosinophilia [13]. In addition to pro-inflammatory activity, eosinophils may interact with airway nerves through CCR3 signaling, increasing acetylcholine release and involving in bronchoconstriction [14].

Furthermore, CCR3/eotaxin axis may have additional functions other than eosinophils recruitment. Farahi et al. recently suggests that human pulmonary artery endothelial
Fig. (1). Signaling pathways of CC chemokine receptor (CCR). PLC: phospholipase C; PIP2: phosphatidylinositol-4,5-bisphosphate; IP3: inositol 1,4,5-trisphosphate; Rho: ras homolog gene family; ROCK: Rho-associated coiled-coil-containing kinase; Mrlc: myosin regulatory light chain; DAG: diacylglycerol; PKC: protein kinase C; Nadph: nicotinamide adenine dinucleotide phosphate; LIMK: LIM-motif-containing kinase; GEF: guanine nucleotide-exchange factor; Cdc42: small GTPase of the Rho family; Dia: Diaphanous formin protein family; MLCK: myosin light-chain kinase; PI4P5K: phosphoinositol 4-phosphate 5-kinase; WASp: Wiskott Aldrich Syndrome protein; PAK: p21-activated kinases; IRSp53: Insulin receptor substrate protein 53; Nox: NADPH oxidase; PI3K: phosphoinositide 3-kinase; Ptk: protein tyrosine kinase; ERK: extracellular-signal-regulated kinase; MEK: mitogen-activated protein kinase/ERK kinase; JAK: Janus kinase; STAT: signal transduction and activator of transcription.

Table 2. Polymorphisms and Pulmonary Diseases in the CC Subfamily

<table>
<thead>
<tr>
<th>Ligand</th>
<th>Polymorphism</th>
<th>Location</th>
<th>Symbol</th>
<th>Disease Involved</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCL1</td>
<td>SNP (A/T)</td>
<td>Intron 2</td>
<td>rs2282691</td>
<td>Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>CCL2</td>
<td>SNP -2518 (G/A)</td>
<td>Promoter</td>
<td>rs1024611</td>
<td>Asthma, Pulmonary tuberculosis</td>
</tr>
<tr>
<td>CCL5</td>
<td>SNP -403 (G/A)</td>
<td>Promoter</td>
<td>rs2107538</td>
<td>Allergic rhinitis, Atopy and Asthma</td>
</tr>
<tr>
<td>CCL11</td>
<td>SNP -576 (C/T)</td>
<td>Promoter</td>
<td>rs4795896</td>
<td>Asthma</td>
</tr>
<tr>
<td>CCL24</td>
<td>SNP +179 (T/C)</td>
<td>Intron 1</td>
<td>rs2302004</td>
<td>Asthma</td>
</tr>
<tr>
<td>CCL26</td>
<td>SNP +77 (C/T)</td>
<td>Intron 2</td>
<td>rs2240478</td>
<td>Asthma</td>
</tr>
</tbody>
</table>

cells have a capacity of elaborating and secreting CCL11, inhibiting apoptosis in human eosinophils [15]. This indicates a mechanism for the aberrant survival of eosinophils in airway allergic inflammation. Additionally, CD11b(+) CD11c(int) macrophages expressing CCR3 as key pro-inflammatory cells were found to be both necessary and sufficient for allergen-specific T cell stimulation during development of eosinophiosis-dominated airway inflammation [16]. The expression of CCR3 on airway smooth muscle cells (ASMC) was increased in asthmatics, and that a CCR3 ligand such as eotaxin could induce migration of ASMC in vitro. Those results suggest that eotaxin could be involved in the increased smooth muscle mass observed in asthmatics through the activation of CCR3 [9]. ASMC has been consid-
CCL22/Monocyte Derived Chemokine and CCL17/Thymus- and Activation-Regulated Chemokine. CCR4, together with CCR3 and CCR8, characterizes polarized Th2 lymphocytes, which migrate selectively in response to its ligands produced by monocytes, dendritic cells, and airway epithelial cells. The production of CCR4 was elevated after the stimulation with Th2 cytokines, suggesting an amplification circuit of polarized Th2 responses and a role for CCR4 in allergic airway inflammation [8, 10, 22, 23]. An absolute requirement of CCR4 for T-lymphocytes was noted during the induction and maintenance of airway inflammation [10]. The majority of T-lymphocytes present in bronchial biopsies from atopic asthmatics were CCR4-positive and were presumably recruited via CCL22 and CCL17 [22].

The pulmonary localization of iNKT cells critical for the induction of airway hyperreactivity required CCR4 expression on iNKT cells [24]. Experimental studies suggest that a more complex level of organization, with CCR4 marking a major subset of circulating non-intestinal memory T-
lymphocytes of both Th1 and Th2 potential, acted as a major trafficking receptor for systemic memory T-lymphocytes [25]. The CCR4/CCL17/CCL22 axes have been reported to play a pivotal role in the late phase allergic reaction. Studies have shown that repeated allergen challenge results in an increase in the number of CCR4+ T-lymphocytes within the airways which can be reduced by treatment with specific blocking antibodies [10]. Another study on transgenic mice and antibody blockade revealed that CCL17-CCR4 interaction dramatically impaired the pulmonary antifungal response during fungal asthma in neutropenic mice [26].

**CCR8**

CCR8 is a specific receptor for the chemokine CCL1/I-309, which is the predominant chemokine secreted from IgE-activated human and mouse mast cells and was elevated in asthmatic airways. CCR8 is expressed by approximately 70% of CD4-positive T lymphocytes recruited to the asthmatic airways, and the number of CCR8-expressing cells increased 3-fold in the airways of asthmatics, as compared with normal volunteers [27], similar to the findings in earlier studies [22]. There was a conflicting result, suggesting that the CCR8-CCL1 axis was not important for Th2 cell recruitment to the inflamed lung [10].

A recent study showed that neutralization of CCL1 or CCR8 deficiency could reduce mucosal lung inflammation, airway hyperresponsiveness, and mucus hypersecretion to a similar degree as detected in mast cell-deficient mice. Adenoviral delivery of CCL1 to the lungs of mast cell-deficient mice restored airway hyperresponsiveness, lung inflammation, and mucus hypersecretion to the degree observed in wild-type mice. The consequences of CCR8 deficiency, including a marked reduction in Th2 cytokine levels, were comparable with those observed by depletion of CD4-positive T lymphocytes [27]. Thus, mast cell-derived CCL1 and CCR8-expressing CD4(+) effector T lymphocytes play an essential role in orchestrating lung mucosal inflammatory responses. The enhanced innate immune response in the absence of CCR8 promoted the rapid clearance of fungal material from the lung, facilitating the remission of fungal asthma [28], suggesting that CCR8 might be an attractive target in fungal-allergic asthma and other fungal-associated pulmonary diseases.

**Other CCRs**

In addition, other CCRs have also been reported to be involved in the pathogenesis of allergic airway inflammation, such as CCR1, CCR2 [8, 29], CCR7 [30-33], CCR9 [34]. CCR1 is expressed on basophils, monocytes and memory T cells and has been reported to be expressed at high levels on the eosinophils of around 15-20% of asthmatics [10]. Presently, CCR1 is believed to be more involved in
virally exacerbated allergic asthma than other types of asthma [35,36]. The expression of CCR1 and its functionality on ASMCs indicates that CCR1 may be involved in the pathogenesis of asthma, through the activation of ASMC by its ligands [37]. Therapeutic application was implied by the significant effect of nonpeptide CCR1 antagonist on fungus-associated allergic asthma [38]. CCR5 and CXCR3 have been reported to play important roles in the lung T-cell homing pathway, and may be potential targets for asthma therapy.

Several promising drugs, e.g. antisense oligonucleotide therapy targeting the receptors for eotaxin (CCR3) and IL-5, IL-3, and granulocyte macrophage colony-stimulating factor are studied in humans, revealing that TPI ASM8 attenuates the allergen-induced increase in target gene mRNA and airway responses in subjects with mild asthma [39].

ROLE IN COPD

COPD is characterized by a chronic inflammatory response of the airways and lungs to noxious particles and gases, mostly cigarette smoke. Pathologically characteristic of COPD include airway wall thickening, peri bronchial fibrosis, peribronchial lymphoid follicles and destruction of lung parenchyma. Although the mechanisms of these changes remain unclear, there is now growing evidence that the recruitment of inflammatory cells in response to cigarette smoke is largely regulated by chemokines as ligands for chemokine receptors, e.g. CCR5 and CCR6 (Fig. 3). In patients with COPD, several CC-chemokines like MIP-1α, MIP-3α and RANTES are upregulated [40-42], suggesting the contribution of their respective receptors in the pathogenesis of the disease. Such results have also been demonstrated in chronic cigarette smoke-exposure model [43, 44].

There was a negative correlation between FEV(1) percentage of predicted, FEV(1)/FVC ratio, and the levels of chemokines analyzed [40].

In the airway infiltration of dendritic cells (DCs), CCR6 at mRNA and protein levels was highly expressed in COPD patients. The interaction between CCL20 (MIP-3α, the ligand for CCR6) and CCR6 provides a possible mechanism for accumulation of DCs in the lungs in COPD [42]. Major chemokine elements are produced by CD1a-positive DCs, of which levels of ligands for CCR5 and CXCR3 are correlated with disease severity. They potentially mediate CD8-positive T-cell infiltration during COPD progression, and CD1a-positive mucosal-associated DCs may sustain CD8-positive T-cell recruitment and/or retention [41]. Those contributions of CCR5 and CCR6 have been further confirmed by an attenuated accumulation of inflammatory cells like macrophages, dendritic cells, neutrophils and CD8-positive T-lymphocytes upon cigarette smoke-exposure in gene knock-out mice [43,44]. Moreover, mice deficient for CCR5 or CCR6 were found to be partially protected from the development of pulmonary emphysema [43, 44]. However, cigarette smoke-induced airway wall remodeling still occurred, suggesting that the mechanisms of the airway inflammation may differ from those for airway remodeling. Eotaxin and CCR3 were also found to be up-regulated and involved in the recruitment of eosinophils and CD4+ lymphocytes into the airways which occur during acute exacerbations of chronic bronchitis [45]. These evidences suggest that chemokine receptors are potential therapeutic targets to reduce the chronic inflammation and parenchymal destruction in COPD.

ROLE IN ALI/ARDS

ALI and ARDS not only are critical cases of respiratory medicine, but also complicate many disease states and are central components of the systemic diseases, such as shock, trauma, severe infection, acute pancreatitis [46]. The uniform pathologic features of ARDS may involve sequestration of activated inflammatory cells and microvascular injury within the lung. A linkage between the cytokine (e.g., TNF-α) and chemokine systems in the genesis of these syndromes may be postulated [47]. The deletion of CCR1 receptor, receptor for MIP-1α and RANTES was noticed to protect from pulmonary inflammation secondary to acute pancreatitis, associated with decreased levels of TNF-α [47]. It indicates that the activation of the CCR1 receptor is an early event in the systemic inflammatory response. Administration of CCR1 antagonist, BX471, significantly protected mice against lung injury associated with cerulein-induced pancreatitis by attenuating myeloperoxidase activity, an indicator of neutrophil recruitment, and lung morphological changes in histological sections [48].

These results suggest that CC chemokine receptors may be involved in neutrophil trafficking in humans [49-51]. However, the main neutrophil chemokine receptors are CXCR1 and CXCR2 in human [1], indicating that MIP-1α and CCR1 may be involved in rodents, while IL-8 and CXCR-1 in humans [47]. Data from transgenic mice suggested that the MCP-1/CCR2 signalling pathway may be involved in the protection against hyperoxia-induced ALI by suppressing production of inducible nitric oxide synthase and reactive oxygen species by activated alveolar macrophages [52].

AIRWAY REMODELING

Airway remodeling in asthma generally includes the increase of epithelial players, basement membrane thickening, extracellular matrix deposition, and goblet cell and ASMC number and size [53]. CCRs are proposed to play essential role in the pathogenesis of airway inflammation in asthma. For example, the CCR1/CCL3 axis was proposed to be associated with the development of the remodeling in a murine model of chronic fungal-induced allergic airway disease [54]. Significantly lower levels of Th2 cytokines were observed in the lungs of CCR1 deficient mice compared with their wild type counterparts, which correlated with significantly less fibrosis. This was confirmed by the therapeutic effect of CCR1 antagonist in a model of chronic fungal asthma [38].

Similar function of CCR8 was also noticed by altering the innate immune response [28].

CCR3 was found to play a role in the allergic airway inflammation and remodeling in the IL-13 gene-modified model of airway remodeling [55], evidenced by a clear reduction of IL-13-induced eosinophil recruitment into the lung lumen in the absence of eotaxin-2 or CCR3. It was correlated with attenuation in IL-13-induced mucus cell metaplasia and collagen deposition. In vitro studies demonstrated that CCR3 has a direct and selective profibrogenic effect on lung and bronchial fibroblasts [56], a novel mechanism by
which eotaxin/CCR3 pathway may be involved in airway remodeling in asthma. In addition, the preventive effect of CCR3 antagonist on airway remodeling was noted in a chronic model of asthma [20]. Antagonizing CCR3 may be a new approach toward a promising asthma therapy.

**ROLE IN FIBROSIS**

Pulmonary fibrosis is characterized by the accumulation of fibroblasts, myofibroblasts, collagen, and other extracellular matrix proteins in the interstitial tissue of the lung, with subsequent scarring and destruction of the alveolar capillary interface. CCRs may play an important role in the pathogenesis of interstitial lung disease and be a potential tool for the disease treatment. MCP-1 was found to stimulate fibroblast collagen expression via specific receptors and endogenous up-regulation of TGF-β expression [57]. CCR2(-/-) mice had less lung fibrosis in both the FITC and bleomycin pulmonary fibrosis models, accompanied by increased levels of GM-CSF and reduced levels of TNF-α [58]. CCR2 deficiency may improve the outcome of the disease by down-regulating macrophage infiltration, macrophage-derivated MMP-2 and MMP-9 production, fibrogenic cytokine expression and fibroblast responsiveness to TGF-β [59,60].

Over-expression of CCR7 was found in idiopathic interstitial pneumonias and primary fibroblast lines, and systemic immunoneutralization of either CCR7 or its ligand significantly attenuated the pulmonary fibrosis in a mouse model of pulmonary fibrosis [61]. The exposure of CCL21 induced a significant migratory and proliferating response, which was inhibited by pertussis toxin or CCR7 antibodies [62]. CCR3 is considered to be involved in the development of lung fibrosis, evidenced by a significant protective function of blocking CCL11 and CCR3 interaction in mice [63].

**EXPERT COMMENTARY**

Chemokines act as regulatory molecules responsible for leukocyte maturation, trafficking, homing and inflammation in respiratory diseases. It is clear that chemokines and their receptors play the critical role in the initiation and development of respiratory diseases, possibly associated with the prognosis of patients, evidenced by the antagonism of the chemokine-CCR network. The inhibition of one single chemokine/chemokine receptor axis or knockout of the single gene has partial effects on the inhibition of these responses. The challenge for us is to discover and develop wider inhibition of CCRs and reach the optimal therapeutic or preventive efficacy with the least side effect. Thus, it is important to understand the potential role of CCRs in respiratory diseases and it may provide exciting new targets for therapeutic intervention.

**FIVE-YEAR VIEW**

It is important to prove the involvement of CCRs in the pathogenesis of lung diseases, but even more valuable to understand the correlation of CCR intracellular signal with lung diseases, duration, severity and prognosis. It is also important to clarify the significance of CCRs in the pathogenesis of lung diseases, either as a critical and unique player, an assistant or accelerator. There is a great need to discover and develop drugs interfering chemokine network or CCR inhibitor treating or preventing human diseases. It is reasonable for us to be positive on the future of this strategy, even though there is the possibility that inhibition of CCRs may lead to disruption of immune defense and immune surveillance, causing other drug-secondary severe infection or tumor. Thus, it is important to increase the understanding of the potential role of CCRs in human diseases and find appropriate approach to reach the balance and develop new drugs for therapeutic intervention.

**ACKNOWLEDGEMENT**

Authors thank BingRui Yang and YiChen Jia for their contributions on the preparation of figures. This work was supported by grants from the Shanghai Leading Academic Discipline Project (Project Number: B115).

**FINANCIAL & COMPETING INTEREST DISCLOSURE**

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

**KEY ISSUES**

1. Chemokine receptors are not only expressed by circulating cells, but also by tissue resident cells, such as ASMC, to play an important role during episodes of tissue inflammation and injury, and in the pathogenesis of diseases.

2. There is strong evidence to confirm the role of chemokines and their receptors, including CCR3, CCR4, CCR8, and CCR1, in the development of allergic inflammation.

3. Recruitment of inflammatory cells in response to cigarette smoke is largely regulated by chemokines as ligands for chemokine receptors, e.g. CCR5 and CCR6.

4. CCR1 may be involved in the pathogenesis of ALI/ARDS via neutrophil trafficking, CCR2, CCR8 and CCR3 are considered as players in the development of lung fibrosis.

5. There is a clear need to develop CCR-specific inhibitors and figure out the balance between the effects and toxicities. It is also crucial to have a humanized in vivo system to screen the drug efficacy and binding, since it is common that the phenotypes of CCRs in animals differ from those of humans.

**REFERENCES**


Potential Role of CC Chemokine and their Receptors


Journal of Epithelial Biology and Pharmacology, 2008, Volume 1


